JP2019517504A5 - - Google Patents

Info

Publication number

JP2019517504A5

JP2019517504A5 JP2018563008A JP2018563008A JP2019517504A5 JP 2019517504 A5 JP2019517504 A5 JP 2019517504A5 JP 2018563008 A JP2018563008 A JP 2018563008A JP 2018563008 A JP2018563008 A JP 2018563008A JP 2019517504 A5 JP2019517504 A5 JP 2019517504A5

Authority

JP

Japan

Prior art keywords

months

antibody

subject

weeks

dose

Prior art date

2017-06-01

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 8
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 4
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 4
• 229960003901 dacarbazine Drugs 0.000 claims 4
• 229960004679 doxorubicin Drugs 0.000 claims 4
• 238000011282 treatment Methods 0.000 claims 4
• 229960003048 vinblastine Drugs 0.000 claims 4
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 4
• 208000017604 Hodgkin disease Diseases 0.000 claims 3
• 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
• 229960003301 nivolumab Drugs 0.000 claims 3
• 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 2
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 2
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
• 230000037396 body weight Effects 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
• 230000004083 survival effect Effects 0.000 claims 2
• 108010006654 Bleomycin Proteins 0.000 claims 1
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 239000000427 antigen Substances 0.000 claims 1
• 108091007433 antigens Proteins 0.000 claims 1
• 102000036639 antigens Human genes 0.000 claims 1
• 229960001561 bleomycin Drugs 0.000 claims 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
• 229960000455 brentuximab vedotin Drugs 0.000 claims 1
• 102000048362 human PDCD1 Human genes 0.000 claims 1
• 229960002621 pembrolizumab Drugs 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 claims 1
• 230000006641 stabilisation Effects 0.000 claims 1
• 238000011105 stabilization Methods 0.000 claims 1
• 238000009168 stem cell therapy Methods 0.000 claims 1
• 238000009580 stem-cell therapy Methods 0.000 claims 1